Telix Total Debt To Capitalization from 2010 to 2024

TLX Stock   15.60  0.17  1.08%   
Telix Pharmaceuticals Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization will likely drop to 0.06 in 2024. During the period from 2010 to 2024, Telix Pharmaceuticals Total Debt To Capitalization regression line of annual values had r-squared of  0.01 and arithmetic mean of  2.78. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.05802611
Current Value
0.0551
Quarterly Volatility
8.75081432
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 1.1 M, Depreciation And Amortization of 7.1 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.41, Days Sales Outstanding of 45.23 or Average Payables of 1.8 M. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Latest Telix Pharmaceuticals' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Telix Pharmaceuticals Limited over the last few years. It is Telix Pharmaceuticals' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Very volatile
   Total Debt To Capitalization   
       Timeline  

Telix Total Debt To Capitalization Regression Statistics

Arithmetic Mean2.78
Geometric Mean0.67
Coefficient Of Variation315.09
Mean Deviation4.18
Median0.59
Standard Deviation8.75
Sample Variance76.58
Range36.2199
R-Value(0.08)
Mean Square Error81.99
R-Squared0.01
Significance0.79
Slope(0.15)
Total Sum of Squares1,072

Telix Total Debt To Capitalization History

2024 0.0551
2023 0.058
2022 0.12
2021 0.54
2020 0.0272
2019 -2.08
2018 -1.08

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Debt To Capitalization 0.06  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.